Organism: Homo sapiens
Gene: 39221_at
Selected probe(set): 207697_x_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 39221_at (207697_x_at) across 6674 perturbations tested by GENEVESTIGATOR:

Relative Expression (log2-ratio):4.8507233
Number of Samples:2 / 2

Experimental	LPS study 4 (shRNA contr.)
	MONO-MAC-6 (MM6) cells were transduced with a control shRNA and then treated with 10 ng/ml lipopolysaccharide (LPS). ATC code:---
Control	mock treated / transduced MONO-MAC-6 cell sample
	MONO-MAC-6 (MM6) cells were transduced with a control shRNA and then mock treated.

Relative Expression (log2-ratio):4.368822
Number of Samples:2 / 2

Experimental	LPS study 4
	MONO-MAC-6 (MM6) cells were treated with 10 ng/ml lipopolysaccharide (LPS). ATC code:---
Control	mock treated MONO-MAC-6 cell sample
	MONO-MAC-6 (MM6) cells mock treated.

Relative Expression (log2-ratio):3.6708431
Number of Samples:2 / 2

Experimental	LPS study 4 (shRNA cycT1)
	MONO-MAC-6 (MM6) cells were transduced with shRNA against cyclin T1 and then treated with 10 ng/ml lipopolysaccharide (LPS). ATC code:---
Control	cycT1 depletion study 2 (shRNA)
	MONO-MAC-6 (MM6) cells were transduced with shRNA against cyclin T1 and then mock treated.

Relative Expression (log2-ratio):3.508524
Number of Samples:4 / 4

Experimental	B-CLL study 11 (rolipram)
	Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. PBMCs’ samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l. ATC code:---
Control	rolipram study 4 (normal T-cell; 20uM)
	MACS purified T-cells from healthy donor peripheral blood treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. ATC code:---

Relative Expression (log2-ratio):-3.3780527
Number of Samples:2 / 2

Experimental	expO ovary cancer study 1 (granulosa cell tumor, malignant; metastatic)
	Metastatic tumor tissue samples obtained from patients with primary granulosa cell tumor of the ovary.
Control	expO ovary cancer study 1 (dysgerminoma; metastatic)
	Metastatic tumor tissue samples obtained from patients with primary dysgerminoma of the ovary.

Relative Expression (log2-ratio):-3.359974
Number of Samples:3 / 3

Experimental	dendritic cell study 7 (IL-4 mddc)
	Mature IL-4 dendritic cells differentiated from CD14+ monocytes obtained from healthy donors. Monocytes were seeded in RPMI and supplemented with 2.5 % heat-inactivated human AB serum. Monocytes were cultured with 800 IU/mL granulocyte macrophage colony-stimulating factor and 20 ng/mL IL-4 in order to generate immature IL-4 DCs. Conventional maturation cocktail, comprising 10 ng/mL tumor necrosis factor-α, 10 ng/mL interleukin-1β, 15 ng/ml interleukin-6 and 1 µg/mL prostaglandin E2 was added for 48 hours. CD14+ monocytes were isolated from peripheral blood mononuclear cells (PBMC) by Ficoll density gradient centrifugation and purified by positive magnetic cell selection.
Control	dendritic cell study 7 (IL-15 mddc)
	Mature IL-15 dendritic cells differentiated from CD14+ monocytes obtained from healthy donors. Monocytes were seeded in RPMI and supplemented with 2.5 % heat-inactivated human AB serum. Differentiation was induced with 800 IU/mL granulocyte macrophage colony-stimulating factor and 200 ng/mL IL-15 to obtain immature IL-15 DCs. A TLR-activating maturation cocktail, comprising 3 µg/mL R848, 2.5 ng/mL tumor necrosis factor-α, 250 ng/mL interferon-γ and 1 µg/mL prostaglandin E2 was added after 24-48 hours of differentiation for 18-20 hours. CD14+ monocytes were isolated from peripheral blood mononuclear cells (PBMC) by Ficoll density gradient centrifugation and purified by positive magnetic cell selection.

Relative Expression (log2-ratio):3.2430735
Number of Samples:4 / 4

Experimental	B-CLL study 11 (DMSO)
	Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with vehicle (DMSO) for 4 hours. PBMCs’ samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l.
Control	vehicle (DMSO) treated normal T-cell sample
	MACS purified T-cells from healthy donor peripheral blood treated with vehicle (DMSO) for 4 hours.

Relative Expression (log2-ratio):-3.225276
Number of Samples:36 / 74

Experimental	AML study 1 (t(15;17)(q22;q11-12))
	Bone marrow samples of patients with acute promyelocytic leukemia [subtype of acute myeloid leukemia (AML)] with genetic aberration (t(15;17)(q22;q11-12)/PML-RARα and variations).
Control	normal bone marrow sample
	Non-leukemic and healthy bone marrow sample.

Relative Expression (log2-ratio):3.1788597
Number of Samples:7 / 8

Experimental	dendritic cell study 6 (gardiquimod)
	Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors and treated with gardiquimod (TLR7 agonist) for 3 hours. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+.
Control	dendritic cell study 6 (untreated)
	Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+.

Relative Expression (log2-ratio):3.1220741
Number of Samples:6 / 8

Experimental	skin transplantation study 1 (3d)
	Human skin punch biopsy from patients after skin grafting. Sample was taken at the site of re-epithelialization 3 days after surgery.
Control	normal skin tissue (skin grafting)
	Skin biopsy samples from healthy control subjects after breast or abdomen reduction surgery.